Here's Why Moderna Shares Are Trading Higher After Q1 Earnings Today

  • Moderna Inc MRNA reports a Q1 EPS of $8.58, compared to the $2.84 posted a year ago, handsomely beating the consensus estimate of $5.21.
  • Total revenue was $6.1 billion compared to $1.9 billion in Q1 FY21, primarily due to increased product sales. The revenue consensus was $4.43 billion.
  • Product sales were $5.9 billion from the Company's COVID vaccine sales, compared to $1.7 billion a year ago.
  • Operating income more than doubled to $4.23 billion from $1.27 billion a year ago.
  • Moderna expects to have four programs in Phase 3 in Q2, including omicron-containing bivalent COVID booster, flu, RSV, and CMV.
  • The company held cash, cash equivalents, and investments as of March 31 of $19.3 billion.
  • Outlook: Moderna has signed 2022 Advanced Purchase Agreements for approximately $21 billion in product sales ($19 billion earlier).
  • The company believes that COVID market dynamics will result in sales slightly larger in 2H of 2022 than in 1H.
  • Price Action: MRNA shares are up 7.27% at $157.20 during the premarket session on the last check Wednesday.
  • Photo by mufidpwt via Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!